502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors
Titel:
502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors
Auteur:
Hong, D.S. Papadopoulos, K. Kim, D.W. Parikh, A. Barve, M. Powderly, J. Starodub, A. Strickler, J. Li, B.T. Oberstein, P. Yu, W. Bitman, B. Lally, S. Lin, W. Sohoni, S. Spira, A.